Potential prognostic and diagnostic application of a novel monoclonal antibody against keratinocyte growth factor receptor

Mol Biotechnol. 2014 Oct;56(10):939-52. doi: 10.1007/s12033-014-9773-x.

Abstract

KGFR is involved in the pathogenesis of several human cancers. In this study, we generated and characterized a monoclonal antibody specific to KGFR (SC-101 mAb) and evaluated its potential use in basic research and as a diagnostic and prognostic tool. The specificity and biological activity of the SC-101 mAb were evaluated by Western blotting, immunofluorescence, and immunoprecipitation analyses on various cell lines. KGFR expression in breast, pancreatic, and thyroid carcinoma was assessed by immunohistochemistry (IHC) with SC-101 mAb. KGFR expression levels revealed by SC-101 mAb resulted to increase proportionally with tumor grade in breast and pancreatic cancer. In addition, SC-101 mAb was able to detect KGFR down-modulation in thyroid cancer. SC-101 mAb might represent a useful tool for basic research applications, and it could also contribute to improve the accuracy of diagnosis and prognosis of epithelial tumors.

MeSH terms

  • Antibodies, Monoclonal*
  • Antibody Specificity / immunology
  • Cell Line, Tumor
  • Fibroblast Growth Factor 7 / pharmacology
  • Fluorescent Antibody Technique
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Neoplasms / diagnosis*
  • Neoplasms / immunology
  • Prognosis
  • Receptor, Fibroblast Growth Factor, Type 2 / genetics
  • Receptor, Fibroblast Growth Factor, Type 2 / immunology*
  • Receptor, Fibroblast Growth Factor, Type 2 / metabolism

Substances

  • Antibodies, Monoclonal
  • Fibroblast Growth Factor 7
  • Receptor, Fibroblast Growth Factor, Type 2
  • keratinocyte growth factor receptor